Skip to content
DataLookout
Menu

AAVIATENCT04514653

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

StatusActive, Not Recruiting
PhasePhase 2
SponsorAbbVie
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 11 versions: 10 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 17 words
    • Primary completion date changed from estimate of Aug 2026 to Oct 13, 2026
    • Secondary endpoints: details revised at 1 of 14 entries
    • Site details revised at 18 of 18 sites
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 140 to confirmed 146
    • Site details revised at 18 of 18 sites
    v10
  3. Notable Primary completion date: Oct 21, 2025 to Aug 2026v9 Show 11 more changesShow less
    • Eligibility criteria expanded, about 8 words
    • Primary endpoint revised
    • Enrollment target: 115 to 140
    • Study sites: 15 to 18
    • Study completion date: Aug 1, 2026 to Feb 2027
    • Interventions: Local Steroid (Drug), RGX-314 Dose 1 (Genetic), RGX-314 Dose 2 (Genetic), RGX-314 Dose 3 (Genetic), Ranibizumab (Biological), Topical… to ABBV-RGX-314 Dose 1 (Genetic), ABBV-RGX-314 Dose 2 (Genetic), ABBV-RGX-314 Dose 3 (Genetic), ABBV-RGX-314 Dose 4 (Genetic), Local Steroid…
    • Secondary endpoints: 7 to 14
    • Study description expanded, about 50 words
    • Study arms: 6 to 7
    • Collaborators expanded, about 2 words
    • Study title shortened, about 1 word
  4. Notable Primary completion date: Oct 2023 to Oct 21, 2025
    • Study completion date: Jan 2024 to Aug 1, 2026
    • Interventions: Local steroid (Drug), RGX-314 Dose 1 (Genetic), RGX-314 Dose 2 (Genetic), RGX-314 Dose 3 (Genetic), Ranibizumab (Biological), Topical… to Local Steroid (Drug), RGX-314 Dose 1 (Genetic), RGX-314 Dose 2 (Genetic), RGX-314 Dose 3 (Genetic), Ranibizumab (Biological), Topical…
    • Study title expanded, about 1 word
    v7
  5. Notable Lead sponsor: REGENXBIO Inc. to AbbVie
    • Collaborators shortened, about 1 word
    v6
Show 4 earlier versionsHide 4 earlier versions
  1. Notable Primary completion date: Mar 2023 to Oct 2023v5 Show 9 more changesShow less
    • Eligibility criteria expanded, about 57 words
    • Enrollment target: 95 to 115
    • Study completion date: Jun 2023 to Jan 2024
    • Interventions: RGX-314 Dose 1 (Biological), RGX-314 Dose 2 (Biological), RGX-314 Dose 3 (Biological), Ranibizumab (LUCENTIS®) (Biological) to Local steroid (Drug), RGX-314 Dose 1 (Genetic), RGX-314 Dose 2 (Genetic), RGX-314 Dose 3 (Genetic), Ranibizumab (Biological), Topical…
    • Secondary endpoints: 5 to 7
    • Study description shortened, about 50 words
    • Site details revised at 5 of 15 sites
    • Study arms: 4 to 6
    • Collaborators expanded, about 1 word
  2. Notable Primary completion date: Jan 15, 2022 to Mar 2023v4 Show 4 more changesShow less
    • Study completion date: Jan 15, 2023 to Jun 2023
    • Start date: Aug 13, 2020 to Aug 25, 2020
    • Study description expanded, about 63 words
    • Site details revised at 2 of 15 sites
  3. Notable Enrollment target: 40 to 95v3 Show 8 more changesShow less
    • Primary completion date: Feb 15, 2021 to Jan 15, 2022
    • Eligibility criteria shortened, about 1 word
    • Study sites: 7 to 15
    • Study completion date: Feb 15, 2022 to Jan 15, 2023
    • Interventions: RGX-314 Dose 1 (Biological), RGX-314 Dose 2 (Biological), Ranibizumab (LUCENTIS®) (Biological) to RGX-314 Dose 1 (Biological), RGX-314 Dose 2 (Biological), RGX-314 Dose 3 (Biological), Ranibizumab (LUCENTIS®) (Biological)
    • Secondary endpoints: details revised at 1 of 5 entries
    • Study description expanded, about 51 words
    • Study arms: 3 to 4
  4. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary endpoint revised
    • Start date changed from estimate of Aug 14, 2020 to Aug 13, 2020
    • Secondary endpoints revised (5)
    • Site details revised at 7 of 7 sites
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Mean change from baseline in BCVA to Week 40 based on the Early Treatment Diabetic Retinopathy Study (ETDRS) score
Timeframe: 40 weeks

Secondary (14)

Incidence of overall and ocular adverse events (AEs) and serious adverse events (SAEs)
Vector shedding analysis in serum, urine, and tears
Proportion of participants who experience ocular inflammation following SCS ABBV-RGX-314 administration
Mean change from baseline in choroidal neovascularization (CNV) lesion size and leakage area based on fluorescein angiography (FA)
Mean change from baseline in BCVA based on ETDRS score
Show 9 moreShow less
Proportion of participants (1) gaining ≥ 15, ≥ 10, ≥ 5, or ≥ 0 letters; (2) losing ≥ 15, ≥ 10, ≥ 5, or > 0 letters (3) maintaining vision (not losing ≥ 15 letters) compared with baseline as per BCVA
Mean change from baseline in CRT as measured by SD-OCT
Mean supplemental anti-VEGF injection annualized rate in the ABBV-RGX-314 treatment arms
Proportion of participants who have a reduction of ≥ 50% and ≥ 75% in supplemental anti-VEGF- injection annualized rate
Proportion of participants with 0, ≤ 1, and ≤ 2 supplemental injections
Mean percent reduction in supplemental anti-VEGF injection annualized rate
Time from ABBV-RGX-314 administration to first supplemental anti-VEGF injection
Aqueous humor ABBV-RGX- 314 TP concentration over time
Mean change from baseline in serum ABBV-RGX-314 TP concentration over time

Arms and interventions

Ranibizumab controlActive comparator

Control treatment arm

ABBV-RGX-314 Treatment Arm (Dose 1)Experimental

ABBV-RGX-314 Dose 1

ABBV-RGX-314 Treatment Arm (Dose 2)Experimental

ABBV-RGX-314 Dose 2

ABBV-RGX-314 Treatment Arm (Dose 3)Experimental

ABBV-RGX-314 Dose 3

ABBV-RGX-314 Treatment Arm (Dose 3) and Local SteroidExperimental

ABBV-RGX-314 Dose 3 and Local Steroid

ABBV-RGX-314 Treatment Arm (Dose 3) and Topical SteroidExperimental

ABBV-RGX-314 Dose 3 and Topical Steroid

ABBV-RGX-314 Treatment Arm (Dose 4) and Topical SteroidExperimental

ABBV-RGX-314 Dose 4 and Topical Steroid

Biologicals: Ranibizumab

Genetic: ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3, ABBV-RGX-314 Dose 4

Drugs: Local Steroid, Topical Steroid

Sites

18 sites in 1 country